

Quantitative Imaging Workshop XVIII:
Optimizing Thoracic Imaging
to Detect and Manage Early Lung Cancer/COPD

A population health approach to screening

UW Health Office of Population Health



MSSP 2013 Final Performance Rates

Domain	Measure Number and Description	UW Health
Patient/ Caregiver Experience	ACO #1: Getting Timely Care, Appointments, and Information	82.05
	ACO #2: How Well Your Doctors Communicate	93.23
	ACO #3: Patients' Rating of Doctor	91.91
	ACO #4: Access to Specialists	84.08
	ACO #5: Health Promotion and Education	58.05
	ACO #6: Shared Decision Making	76.05
	ACO #7: Health Status/Functional Status	72.49
Care Coordination/ Patient Safety	ACO #8: Risk Standardized, All Condition Readmissions	13.51
	ACO #9: ASC Admissions: COPD or Asthma in Older Adults	0.73
	ACO #10: ASC Admission: Heart Failure	0.97
	ACO #11: Percent of PCPs who Qualified for Meaningful Use	87.69
	ACO #12: Medication Reconciliation	0
Preventive Health	ACO #13: Falls: Screening for Fall Risk	22.67
	ACO #14: Influenza Immunization	85.77
	ACO #15: Pneumococcal Vaccination	92.17
	ACO #16: Adult Weight Screening and Follow-up	56.06
	ACO #17: Tobacco Use Assessment and Cessation Intervention	92.27
	ACO #18: Depression Screening	0.34
	ACO #19: Colorectal Cancer Screening	79.31
	ACO #20: Mammography Screening	69.39
Diabetes	ACO #21: Proportion of Adults who had blood pressure screened in past 2 years	78.17
	Diabetes Composite: ACO #22: Hemoglobin A1c Control (HbA1c) (<8 percent); ACO #23: Low Density Lipoprotein (LDL) (<100 mg/dL); ACO #24: Blood Pressure (BP) < 140/90; ACO #25: Tobacco Non Use; ACO #26: Aspirin Use	40.09
Diabetes	ACO #27: Percent of beneficiaries with diabetes whose HbA1c in poor control (>9 percent)	9.27
Hypertension	ACO #28: Percent of beneficiaries with hypertension whose BP < 140/90	75.6
IVD	ACO #29: Percent of beneficiaries with IVD with complete lipid profile and LDL control < 100mg/dl	65.39
IVD	ACO #30: Percent of beneficiaries with IVD who use Aspirin or other antithrombotic	91.78
HF	ACO #31: Beta-Blocker Therapy for LVSD	91.6
CAD	CAD Composite: ACO #32. Drug Therapy for Lowering LDL Cholesterol; ACO #33. ACE Inhibitor or ARB Therapy for Patients with CAD and Diabetes and/or LVSD	78.52






Chart Title



Overall performance on all 3 metrics

